OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes
Charlotte C. van Ruiten, Dick J. Veltman, Anouk Schrantee, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 6, pp. e2590-e2599
Open Access | Times Cited: 17
Charlotte C. van Ruiten, Dick J. Veltman, Anouk Schrantee, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 6, pp. e2590-e2599
Open Access | Times Cited: 17
Showing 17 citing articles:
The insulin resistant brain: impact on whole-body metabolism and body fat distribution
Martin Heni
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1181-1191
Open Access | Times Cited: 15
Martin Heni
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1181-1191
Open Access | Times Cited: 15
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
Ziqi Zhang, Qiling Zhang, Ying Tan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 18
Ziqi Zhang, Qiling Zhang, Ying Tan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 18
Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Asma Mousavi, Shayan Shojaei, Hamidreza Soleimani, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Asma Mousavi, Shayan Shojaei, Hamidreza Soleimani, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
Gabriela Dumitriṭa Stanciu, Daniela Carmen Ababei, Carmen Solcan, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1620-1620
Open Access | Times Cited: 8
Gabriela Dumitriṭa Stanciu, Daniela Carmen Ababei, Carmen Solcan, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1620-1620
Open Access | Times Cited: 8
Hypothalamic sex-specific metabolic shift by canagliflozin during aging
Hashan Jayarathne, Ryan Sullivan, Lukas Stilgenbauer, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4479-4493
Open Access | Times Cited: 2
Hashan Jayarathne, Ryan Sullivan, Lukas Stilgenbauer, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4479-4493
Open Access | Times Cited: 2
Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
Charlotte C. van Ruiten, Dick J. Veltman, Madelief Wijdeveld, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 8, pp. 1588-1597
Open Access | Times Cited: 10
Charlotte C. van Ruiten, Dick J. Veltman, Madelief Wijdeveld, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 8, pp. 1588-1597
Open Access | Times Cited: 10
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
Charlotte C. van Ruiten, Dick J. Veltman, Max Nieuwdorp, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 8
Charlotte C. van Ruiten, Dick J. Veltman, Max Nieuwdorp, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 8
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Bhavarth P. Dave, Mehul R. Chorawala, Ishika V Shah, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 1
Bhavarth P. Dave, Mehul R. Chorawala, Ishika V Shah, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 1
Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition
Ho Gyun Lee, Il Hyeon Jung, Byong Seo Park, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 6, pp. 784-795
Open Access | Times Cited: 2
Ho Gyun Lee, Il Hyeon Jung, Byong Seo Park, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 6, pp. 784-795
Open Access | Times Cited: 2
Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
Júlia Richter Hummel, Stephanie Kullmann, Martin Heni
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. e3080-e3081
Open Access | Times Cited: 3
Júlia Richter Hummel, Stephanie Kullmann, Martin Heni
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. e3080-e3081
Open Access | Times Cited: 3
Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
Jae Hyun Bae
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 1, pp. 157-158
Open Access
Jae Hyun Bae
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 1, pp. 157-158
Open Access
Hypothalamic Sex-Specific Metabolic Shift by Canagliflozin during Aging
Hashan Jayarathne, Rebecca Sullivan, Lukas Stilgenbauer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Hashan Jayarathne, Rebecca Sullivan, Lukas Stilgenbauer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The brain as a central regulator of metabolism
Julia Hummel, Martin Heni
Deleted Journal (2024) Vol. 20, Iss. 5, pp. 622-627
Closed Access
Julia Hummel, Martin Heni
Deleted Journal (2024) Vol. 20, Iss. 5, pp. 622-627
Closed Access
Changes in daily intake of nutrients and foods including confectionery after the initiation of empagliflozin in Japanese patients with type 2 diabetes: a pilot study
Toshiko Murayama, Michihiro Hosojima, Hideyuki Kabasawa, et al.
BMC Nutrition (2024) Vol. 10, Iss. 1
Open Access
Toshiko Murayama, Michihiro Hosojima, Hideyuki Kabasawa, et al.
BMC Nutrition (2024) Vol. 10, Iss. 1
Open Access
Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis
Srinivas Martha, Preethi Hepzibah Jangam, Suraj G. Bhansali
The Journal of Clinical Pharmacology (2024)
Closed Access
Srinivas Martha, Preethi Hepzibah Jangam, Suraj G. Bhansali
The Journal of Clinical Pharmacology (2024)
Closed Access
GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating
Matthias Blüher
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 9, pp. 523-524
Closed Access | Times Cited: 2
Matthias Blüher
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 9, pp. 523-524
Closed Access | Times Cited: 2
USE OF SGLT2 INHIBITORS IN TYPE 1 DIABETES: EXPERIENCE FROM A PORTUGUESE TERTIARY CENTER
Mariana Aveiro-Lavrador, Bárbara Araújo, Miguel Melo, et al.
Revista Portuguesa de Endocrinologia Diabetes e Metabolismo (2023), Iss. 2
Open Access
Mariana Aveiro-Lavrador, Bárbara Araújo, Miguel Melo, et al.
Revista Portuguesa de Endocrinologia Diabetes e Metabolismo (2023), Iss. 2
Open Access
